September 23, 2012Current Pharmaceutical Design
Development and Clinical use of Prasugrel and Ticagrelor
Key result
Prasugrel and ticagrelor are newer antiplatelet agents recently licensed for acute coronary syndromes that aim to address limitations of older therapies and improve patient outcomes.
Population
Patients with acute coronary syndromes
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Prasugrel and ticagrelor licensing may expand options beyond prior agent limitations; leaves open comparative effectiveness in broad populations.
Structured PICO
P
Population
Patients with acute coronary syndromes
I
Intervention
Prasugrel and ticagrelor
This review examines the rationale for the development and clinical integration of the newer antiplatelet agents prasugrel and ticagrelor in acute coronary syndromes.
Cite This Study
Ahmad et al. (2012) conducted a review in Acute coronary syndromes. Prasugrel and ticagrelor was evaluated. Prasugrel and ticagrelor are newer antiplatelet agents recently licensed for acute coronary syndromes that aim to address limitations of older therapies and improve patient outcomes.